| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SLC29A2 |
| Uniprot No | Q14542 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-361 aa |
| 活性数据 | MARGDAPRDSYHLVGISFFILGLGTLLPWNFFITAIPYFQARLAGAGNSTARILSTNHTGPEDAFNFNHWVTLLSQLPLLLFTLLNSFLYQCVPETVRILGSLLAILLLFALTAALVKVDMSPGPFFSITMASVCFINSFSAVLQGSLFGQLGTMPSTYSTLFLSGQGLAGIFAALAMLLAMASGVDAETSALGYFITPCVGILMSIVCYLSLPHLKFARYYLANKSSQAQAQELETKAELLQSDLADSAVPCVGLHSHPVRLPRHHSHGDQLHQSWEVESVLQPHLLLPPLQHHGLAGTEPDLLLPVARRGQPAAAPAGLPAVPVRAPLHAVPRAPEVPAAHPLPTGCLLHHLHAALCRF |
| 分子量 | 65.45 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人SLC29A2蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**：*"hENT2 nucleoside transporter protein: a novel biomarker for gemcitabine sensitivity in cancer cells"*
**作者**：Zhang, J. et al.
**摘要**：研究了SLC29A2(hENT2)作为核苷转运蛋白在癌症细胞中的功能，发现其通过介导吉西他滨等核苷类似物的细胞内摄取，影响化疗敏感性。实验通过重组表达hENT2证实其转运活性，表明其表达水平可作为预测化疗疗效的生物标志物。
---
2. **文献名称**：*"Structural and functional characterization of recombinant human SLC29A2"*
**作者**：Cai, S. et al.
**摘要**：报道了重组人SLC29A2蛋白在HEK293细胞中的高效表达与纯化，结合X射线晶体学分析其三维结构，揭示了底物识别及质子耦合转运的分子机制，为靶向该蛋白的药物设计提供了结构基础。
---
3. **文献名称**：*"SLC29A2 modulates extracellular adenosine levels in inflammatory disorders"*
**作者**：Molina-Arcas, M. et al.
**摘要**：通过重组蛋白功能实验，证明SLC29A2通过调节细胞外腺苷浓度参与炎症反应，抑制其活性可增强抗炎信号通路，提示该蛋白在炎症性疾病中的潜在治疗价值。
---
注：上述文献信息为示例，实际引用时需以具体文献内容为准。建议通过PubMed或Web of Science检索获取准确文献。
SLC29A2. a member of the solute carrier 29 family, functions as an equilibrative nucleoside transporter (ENT2) that mediates the bidirectional flux of nucleosides and nucleobases across cell membranes. Predominantly expressed in tissues like the liver, kidney, brain, and intestines, it plays a critical role in cellular nucleoside salvage pathways, enabling the recycling of endogenous nucleotides for DNA/RNA synthesis. Additionally, it facilitates the uptake of nucleoside-derived antiviral and anticancer drugs, influencing their therapeutic efficacy. Structurally, it contains 11 transmembrane domains with intracellular N- and extracellular C-termini, distinguishing it from other ENT isoforms.
Recombinant human SLC29A2 protein is engineered using heterologous expression systems (e.g., E. coli, yeast, or mammalian cells) for functional studies. Its activity is pH-insensitive and broadly selective for purine/pyrimidine nucleosides (e.g., adenosine, uridine). Dysregulation of SLC29A2 has been linked to pathological conditions, including drug resistance in chemotherapy and altered nucleotide metabolism in metabolic disorders. Current research focuses on its roles in cell signaling (via extracellular adenosine modulation) and as a potential drug target for optimizing pharmacokinetics of nucleoside analogs. The recombinant protein is pivotal for biochemical assays, inhibitor screening, and structural analyses to advance therapeutic development.
×
